ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / FMS / insiders
DVA (74) SHC (49) PGNY (79) AGL (36) ⌘ Pro Terminal →

Fresenius Medical Care AG American (FMS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$22.61 +0.62% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $22.59

Fresenius Medical Care AG American (FMS) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $12.55B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on FMS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is FMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Fresenius Medical Care AG American (NYSE: FMS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $22.61 (+0.62% 1D, market cap $12.55B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, FMS ranks #187 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does FMS compare to DVA and SHC in the Health Care sector?
▼

Within the Health Care sector (Misc Health and Biotechnology Services), FMS carries a Roarable D+ (57/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, DVA (DaVita Inc.) holds a B grade (74/100 RQD, P/E 11.4x, ROIC 29.2%, cap $11.79B) and SHC (Sotera Health Company) posts a D grade (49/100 RQD, P/E 68.5x, ROIC 3.1%, cap $5.18B). Among the 5-stock peer group, DVA leads on earnings multiple (11.4x) while DVA leads on capital efficiency (29.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for FMS?
▼

For Fresenius Medical Care AG American (FMS), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #187 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $22.59 (-0.08%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 6.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510057
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C
Cash (12)Whales (8)SEC (16)Macro (9)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE-0.4% Base Target
$28 Bull$23 Base$18 Bear
📬 FREE FMS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FMS)Realized 20D OHLCV Swing Band: ±4.4%
Deterministic 5-Pillar Attribution (57/100 Composite)
🔍 WHY FMS SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (28% of score)

Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (21% of score)

SEC XBRL Trailing 12 Months: 6.9% FCF Margin ($277.4M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
49
Grade D$21.54+0.1% Next Q
Q2 (-2Q)
52
Grade C-$21.56+4.9% Next Q
Q3 (-1Q)
54
Grade C-$22.62+0% Next Q
Current
57
Grade D+$22.61-0.2% Hist 90D α
Trajectory: D (49) → D+ (57)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the FMS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, FMS faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($22.35) or 200D SMA ($22.89) invalidates the momentum regime and cuts Target Base ($22.51) toward Bear Floor ($17.56).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FMS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “FMS Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 57%NO 43%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

FMS Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (FMS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on FMS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FMS)

  • ✓Walkthrough of FMS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
FMS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -0.18%⚡ TESTING RESISTANCE
2026-11-03O $23.13H $23.13L $22.47C $22.61VOL 968.0K
RES: $23.11SUP: $19.65SMA50: $22.35SMA200: $22.89
$26.87$25.01$23.16$21.30$19.44RES $23.11SUP $19.65$22.612026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FMS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FMS Butterfly Map → + Track FMS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
25.3%/yr Implied 5Y Growth

vs. -3.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on FMS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FMS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for FMS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FMS)

Health Care Rank #187 of 1016 ⚔️ DVA vs FMS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FMS vs. DVA, SHC, PGNY, AGL)

Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Fresenius Medical Care AG American (FMS) ranks #187 by composite RQD confidence (57/100, grade D+) and #90 by equity capitalization ($12.55B). Within this direct 5-issuer industry benchmark cohort, DVA leads on earnings valuation at 11.4x trailing P/E, while DVA leads on capital efficiency and profitability with 29.2% ROIC and — gross margin. PGNY currently holds the highest overall quantitative score in the immediate peer group at 79/100 (B+) compared with FMS at 57/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
FMS ACTIVE
Fresenius Medical Care AG American
D+ 57/100 32.8x — 9.9% +0.62% $12.55B Benchmark Subject
DVA
DaVita Inc.
B 74/100 11.4x — 29.2% -0.94% $11.79B /dva-vs-fms →
SHC
Sotera Health Company
D 49/100 68.5x 55.5% 3.1% -2.26% $5.18B /shc-vs-fms →
PGNY
Progyny Inc.
B+ 79/100 37.2x 23.6% 16.7% +0.75% $2.24B /pgny-vs-fms →
AGL
agilon health inc.
D- 36/100 — — -35.0% +2.04% $1.43B /agl-vs-fms →

2. FMS Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Fresenius Medical Care AG American (FMS) operates in Misc Health and Biotechnology Services (Health Care) with an equity capitalization of $12.55B, trailing P/E of 32.8x, forward P/E of 30.5x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 7/9.

3. FMS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Fresenius Medical Care AG American (NYSE: FMS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $22.61 (+0.62% 1D, market cap $12.55B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, FMS ranks #187 in composite RQD confidence.

How does FMS compare to DVA and SHC in the Health Care sector?

Within the Health Care sector (Misc Health and Biotechnology Services), FMS carries a Roarable D+ (57/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, DVA (DaVita Inc.) holds a B grade (74/100 RQD, P/E 11.4x, ROIC 29.2%, cap $11.79B) and SHC (Sotera Health Company) posts a D grade (49/100 RQD, P/E 68.5x, ROIC 3.1%, cap $5.18B). Among the 5-stock peer group, DVA leads on earnings multiple (11.4x) while DVA leads on capital efficiency (29.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FMS?

For Fresenius Medical Care AG American (FMS), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #187 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FMS trading relative to its 50-day, 200-day, and 52-week technical levels?

FMS last traded at $22.61 (+0.62% on volume of 1,462,453 shares), positioning the stock +1.16% above its 50-day simple moving average ($22.35) and -1.22% below its 200-day simple moving average ($22.89). Across its 52-week range of $20.02 to $26.66, FMS sits at the 39.0% percentile with a 14-day RSI of 50.8 (NEUTRAL RANGE) and an implied next-earnings move of ±4.4% ($21.62 to $23.60).

Direct Sub-Reports: FMS RQD Cockpit FMS 12M Forecast FMS Earnings & Move FMS Dividends & DRIP FMS Insiders & 13F FMS Whale Options FMS Profit Sankey FMS News & Why
ROARABLE RATING BRIEF • RQD 57/100 (D+) ✓ SEC XBRL & RQD VERIFIED

FMS — Fresenius Medical Care AG American: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Fresenius Medical Care AG American (FMS) earns a live Roarable RQD composite score of 57/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $22.61 (+0.62% 1D, market capitalization $12.55B).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of 9.9%, gross margin of —, operating margin of 13.9%, and free cash flow yield of 2.21%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (12/20): Incorporates a 0.90x equity beta, Altman Z-Score of 3.74, Piotroski F-Score of 7/9, and Debt/Equity of 0.39x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Fresenius Medical Care AG American (FMS) is a NYSE-listed issuer in the Health Care sector, within the Misc Health and Biotechnology Services industry..9B. — The products, customers, and revenue model are not described in the source data.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 57/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of 2.21% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $20.02 – $26.66 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 32.8x trailing P/E and 21.0x EV/EBITDA against 13.9% operating margins and a 0.90x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from the source data.

  • Key Question #1: Can FMS sustain or expand its 13.9% operating margin and 9.9% ROIC against Misc Health and Biotechnology Services peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (2.21% FCF yield) strengthen balance-sheet liquidity (Altman Z-Score 3.74) toward the $26.66 52-week high?
  • Key Question #3: How sensitive is FMS's 30.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.90x)?

FMS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Fresenius Medical Care AG American (FMS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to FMS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

FMS Bull vs. Bear Conversation Board — What's Your Call at $22.61?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FMS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on FMS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $29.66 (+32.0%)
📌 Pinned Debate

A 16/20 forensic balance sheet with an Altman Z-Score of 3.74 and a Piotroski F-Score of 7/9 signals financial strength.

Long FMS at $22.47 targeting $29.66. A 16/20 forensic balance sheet with an Altman Z-Score of 3.74 and a Piotroski F-Score of 7/9 signals financial strength.. Institutional whale score is 8/20 and the risk/reward vs. the $20.02 52-week low is skewed heavily in favor of bulls.

CapAlloc_Nerd 🐂 BULL

@TapeReader_Pro Agree on the RQD 57/100 quality, though with 0.9 beta I'm scaling in with half-size at $22.47 and keeping dry powder in case we test $20.90.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $17.08 (-24.0%)
Spot @ $22.47

A 2.21% FCF yield against a 32.8 trailing P/E leaves thin cash returns to support a demanding valuation.

Fading this rally in FMS at $22.47. A 2.21% FCF yield against a 32.8 trailing P/E leaves thin cash returns to support a demanding valuation.. With a beta of 0.9 and the stock sitting at $22.47 (52-wk range $20.02–$26.42), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%